0.8196
Precedente Chiudi:
$0.8672
Aprire:
$0.8728
Volume 24 ore:
1.39M
Relative Volume:
0.58
Capitalizzazione di mercato:
$132.63M
Reddito:
$400.57M
Utile/perdita netta:
$9.21M
Rapporto P/E:
20.49
EPS:
0.04
Flusso di cassa netto:
$146.36M
1 W Prestazione:
+3.64%
1M Prestazione:
+12.92%
6M Prestazione:
-77.91%
1 anno Prestazione:
-87.68%
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Nome
Ironwood Pharmaceuticals Inc
Settore
Telefono
617-621-7722
Indirizzo
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Confronta IRWD con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
IRWD
Ironwood Pharmaceuticals Inc
|
0.8196 | 140.33M | 400.57M | 9.21M | 146.36M | 0.04 |
![]()
ZTS
Zoetis Inc
|
152.82 | 68.32B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.66 | 46.55B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.85 | 43.80B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.33 | 19.01B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
306.41 | 13.79B | 2.99B | 1.21B | 1.13B | 25.06 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-15 | Downgrade | Jefferies | Buy → Hold |
2025-04-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2025-04-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
2024-09-09 | Iniziato | Leerink Partners | Market Perform |
2024-08-08 | Downgrade | CapitalOne | Overweight → Equal Weight |
2024-01-17 | Iniziato | Craig Hallum | Buy |
2023-12-14 | Iniziato | Wells Fargo | Overweight |
2023-11-09 | Iniziato | Jefferies | Buy |
2023-09-28 | Iniziato | JMP Securities | Mkt Outperform |
2022-09-02 | Iniziato | CapitalOne | Overweight |
2022-04-22 | Iniziato | Piper Sandler | Overweight |
2020-09-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2020-06-17 | Iniziato | Northland Capital | Outperform |
2019-07-10 | Ripresa | Credit Suisse | Neutral |
2019-03-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
2019-02-25 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
2019-01-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
2018-11-07 | Downgrade | Credit Suisse | Outperform → Neutral |
2018-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
2018-07-23 | Iniziato | H.C. Wainwright | Sell |
2018-05-09 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2018-01-05 | Downgrade | BofA/Merrill | Buy → Underperform |
2017-12-06 | Downgrade | Mizuho | Buy → Neutral |
2017-07-21 | Downgrade | JP Morgan | Overweight → Neutral |
2017-05-03 | Iniziato | Wells Fargo | Outperform |
2017-04-07 | Reiterato | Mizuho | Buy |
2017-02-22 | Reiterato | Barclays | Equal Weight |
2016-11-04 | Reiterato | Mizuho | Buy |
2016-10-24 | Reiterato | Wedbush | Neutral |
2016-10-10 | Reiterato | Mizuho | Buy |
2016-09-27 | Reiterato | WallachBeth | Hold |
Mostra tutto
Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie
Ironwood Pharmaceuticals Inc: Analyzing IRWD Stock Trends - investchronicle.com
What drives Ironwood Pharmaceuticals Inc. stock priceTriple-digit wealth increases - Autocar Professional
What analysts say about Ironwood Pharmaceuticals Inc. stockHigh-yield market plays - Autocar Professional
Is Ironwood Pharmaceuticals Inc. a good long term investmentRapid portfolio appreciation - jammulinksnews.com
Ironwood Pharmaceuticals Inc. Stock Analysis and ForecastFree Consultation - jammulinksnews.com
How the Irritable Bowel Syndrome (IBS) Treatment Market Will - openPR.com
How Ironwood Pharmaceuticals Inc. stock performs during market volatilityTop Gaining Low Risk Assets - Newser
What makes Ironwood Pharmaceuticals Inc. stock price move sharplyFast Moving Stock Alerts - Newser
Why Ironwood Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Confidence Trade Setups - Newser
Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - The Globe and Mail
Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, And Clinical Trial Landscape Analysis By Delveinsight Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, Abbvie/Neurocrine - MenaFN
Ironwood Pharmaceuticals appoints KPMG as new auditor, dismisses EY By Investing.com - Investing.com Nigeria
Ironwood Pharmaceuticals appoints KPMG as new auditor, dismisses EY - Investing.com
Investor Network: Ironwood Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ironwood Pharmaceuticals, Inc.(NasdaqGS: IRWD) added to Russell 3000E Index - MarketScreener
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Held Back By Insufficient Growth Even After Shares Climb 28% - simplywall.st
Ironwood Pharma Elects Directors at Annual Meeting - TipRanks
Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report? - Yahoo Finance
Ironwood Pharmaceuticals Inc (IRWD) Is A Good Stock To Invest In - Stocksregister
Ameriprise Financial Inc. Trims Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer - GlobeNewswire
Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock By Investing.com - Investing.com India
Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock - Investing.com Australia
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates - MSN
Drug developer stocks fall as companies navigate clinical roadblocks - BioWorld MedTech
Ironwood Pharmaceuticals Inc Azioni (IRWD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):